These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18157384)

  • 41. Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study.
    Jung H; Land C; Nicolay C; De Schepper J; Blum WF; Schönau E
    Eur J Endocrinol; 2009 Feb; 160(2):149-56. PubMed ID: 19039085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency.
    Reiter EO; Lindberg A; Ranke MB; Price DA; Albertsson-Wikland K; Cowell CT; Bakker B
    Horm Res; 2003; 60(Suppl 1):68-73. PubMed ID: 12955021
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year's growth response in GH-deficient children.
    Bozzola M; Radetti G; Pagani S; Draghi M; Aimaretti G; Rondini G
    J Endocrinol Invest; 1999 Nov; 22(10):790-5. PubMed ID: 10614529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.
    Walvoord EC; de la Peña A; Park S; Silverman B; Cuttler L; Rose SR; Cutler G; Drop S; Chipman JJ
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2052-9. PubMed ID: 19336514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone.
    Ogilvy-Stuart AL; Stirling HF; Kelnar CJ; Savage MO; Dunger DB; Buckler JM; Shalet SM
    Clin Endocrinol (Oxf); 1997 May; 46(5):571-8. PubMed ID: 9231053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy.
    Mohn A; Marzio D; Giannini C; Capanna R; Marcovecchio M; Chiarelli F
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):537-42. PubMed ID: 16268806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.
    Wit JM; Rekers-Mombarg LT; Cutler GB; Crowe B; Beck TJ; Roberts K; Gill A; Chaussain JL; Frisch H; Yturriaga R; Attanasio AF
    J Pediatr; 2005 Jan; 146(1):45-53. PubMed ID: 15644821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
    Zenaty D; Garel C; Limoni C; Czernichow P; Léger J
    Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The insulin-like growth factor-I response to growth hormone is increased in prepubertal children with obesity and tall stature.
    Bouhours-Nouet N; Gatelais F; Boux de Casson F; Rouleau S; Coutant R
    J Clin Endocrinol Metab; 2007 Feb; 92(2):629-35. PubMed ID: 17090643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
    Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
    Rappaport R; Mugnier E; Limoni C; Crosnier H; Czernichow P; Leger J; Limal JM; Rochiccioli P; Soskin S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cortical bone density is normal in prepubertal children with growth hormone (GH) deficiency, but initially decreases during GH replacement due to early bone remodeling.
    Schweizer R; Martin DD; Schwarze CP; Binder G; Georgiadou A; Ihle J; Ranke MB
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5266-72. PubMed ID: 14602760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing.
    Counts DR; Silverman LA; Rajicic N; Geffner ME; Newfield RS; Thornton P; Carakushansky M; Escobar O; Rapaport R; Levitsky L; Rotenstein D; Hey-Hadavi J; Wajnrajch MP
    Horm Res Paediatr; 2015; 84(2):79-87. PubMed ID: 25966824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
    Kappelgaard AM; Mikkelsen S; Bagger C; Fuchs GS
    J Pediatr Endocrinol Metab; 2012; 25(3-4):285-94. PubMed ID: 22768658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The association between growth response to growth hormone and baseline body composition of children with growth hormone deficiency.
    Esen I; Demirel F; Tepe D; Kara O; Koc N
    Growth Horm IGF Res; 2013 Oct; 23(5):196-9. PubMed ID: 23890535
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant growth hormone therapy in children with short stature in Kuwait: a cross-sectional study of use and treatment outcomes.
    Al-Abdulrazzaq D; Al-Taiar A; Hassan K; Al-Basari I
    BMC Endocr Disord; 2015 Dec; 15():76. PubMed ID: 26630987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety Outcomes and Near-Adult Height Gain of Growth Hormone-Treated Children with SHOX Deficiency: Data from an Observational Study and a Clinical Trial.
    Benabbad I; Rosilio M; Child CJ; Carel JC; Ross JL; Deal CL; Drop SL; Zimmermann AG; Jia N; Quigley CA; Blum WF
    Horm Res Paediatr; 2017; 87(1):42-50. PubMed ID: 28002818
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of final height in patients with pituitary growth hormone deficiency who were treated with growth hormone replacement].
    Korpal-Szczyrska M; Dorant B; Kamińska H; Birkholz D; Niedźwiecki M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):31-4. PubMed ID: 16704859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
    Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
    J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.